Figures computed from official regulatory filings — .
Analysttarget 14 USD (+1380%) · consensus 5/5 · 2 buy · 0 hold · 0 sell
Ownershipinsiders 9.66% · institutions 9.75% · short 3.7% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Cadrenal Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
11 buys45 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Pham Quang Xtrack record | Sell | $22.4K | SEC |
| Pham Quang Xtrack record | Sell | $27.5K | SEC |
| Pham Quang Xtrack record | Sell | $6.4K | SEC |
| Pham Quang Xtrack record | Sell | $7.3K | SEC |
| Pham Quang Xtrack record | Sell | $32.5K | SEC |
| Pham Quang Xtrack record | Sell | $1.6K | SEC |
| Pham Quang Xtrack record | Sell | $11.5K | SEC |
| Pham Quang Xtrack record | Sell | $51.2K | Unusual size | SEC |
| Pham Quang Xtrack record | Sell | $13.1K | SEC |
| Pham Quang Xtrack record | Sell | $6K | SEC |
| Pham Quang Xtrack record | Sell | $14.7K | SEC |
| Pham Quang Xtrack record | Sell | $52.7K | SEC |
| Pham Quang Xtrack record | Sell | $25.8K | SEC |
| Pham Quang Xtrack record | Sell | $9.9K | SEC |
| Pham Quang Xtrack record | Sell | $9.1K | SEC |
| Pham Quang Xtrack record | Sell | $17.2K | SEC |
| Pham Quang Xtrack record | Sell | $1.6K | SEC |
| Pham Quang Xtrack record | Sell | $1.5K | SEC |
| Pham Quang Xtrack record | Sell | $37.3K | SEC |
| Pham Quang Xtrack record | Sell | $17.4K | SEC |
| Pham Quang Xtrack record | Sell | $14.7K | SEC |
| Pham Quang Xtrack record | Sell | $6.6K | SEC |
| Szot Matthew K | Sell | $69.2K | SEC |
| Golden Lee Scott | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Szot Matthew K | Sell | $25.2K | SEC |